Hikma Pharmaceutical traded at 1,592.50 this Wednesday August 5th, increasing 11.50 or 0.73 percent since the previous trading session. Looking back, over the last four weeks, Hikma Pharmaceutical gained 3.14 percent. Over the last 12 months, its price fell by 15.47 percent. Looking ahead, we forecast Hikma Pharmaceutical to be priced at 1,554.89 by the end of this quarter and at 1,467.93 in one year, according to Trading Economics global macro models projections and analysts expectations.
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 300 products in different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.